Pharma Focus Europe


The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Gilead and Xilio Enter Exclusive License Agreement for Tumor-Activated IL-12 Program

Saturday, March 30, 2024

Gilead Sciences Inc and Xilio Therapeutics Inc have recently announced an exclusive agreement to collaborate on the development and commercialization of Xilios Phase tumoractivated IL program

Confo Therapeutics Secures VLAIO Grant for Advancing Drug Discovery and Development in Endocrine and Metabolic Diseases

Friday, March 29, 2024

Confo Therapeutics a pioneer in the field of developing innovative medicines targeting Gprotein coupled receptors has announced today that it has received a substantial EUR million grant from Flanders

Intravacc and Primrose Bio Collaborate to Enhance Conjugate Vaccine Development

Thursday, March 28, 2024

Intravacc a globally recognized contract development and manufacturing organization specializing in infectious disease and therapeutic vaccines has announced a strategic partnership with Primrose Bio

Essential Pharma and AcedrA Biopharmaceuticals Announce Distribution Agreement to Market Vital Medications in the Middle East and North Africa Region

Wednesday, March 27, 2024

Essential Pharma a global specialty pharmaceutical group dedicated to ensuring sustainable access to

Slingshot Introduces Novel Portfolio Aimed at Advancing Cell Therapy Development, Manufacturing, and Clinical Trials

Wednesday, March 27, 2024

In response to significant customer demand Slingshot Biosciences is unveiling a revolutionary range of products aimed at transforming the landscape of analytical precision in cell therapy

Brain Trust Bio Granted Approval for Clinical Trials on ALS and Other CNS Disorders Utilizing Continuous Intrathecal Drug Delivery Approach

Tuesday, March 26, 2024

Brain Trust Bio a leading innovator in developing treatments for central nervous system disorders has obtained approval to initiate Phase I clinical trials in Australia for its revolutionary Continuous

Andelyn Biosciences and Grace Science, LLC Join Forces to Transfer Technology for Suspensive Process AAV Gene Therapy for NGLY1 Deficiency

Monday, March 25, 2024

Andelyn Biosciences Inc a leading Contract Development and Manufacturing Organization specializing in cell and gene therapy has partnered with Grace Science LLC to facilitate the tech transfer

HI-Bio Granted FDA Orphan Drug Designation for Felzartamab in Treating Antibody-Mediated Rejection in Kidney Transplant Recipients

Friday, March 22, 2024

Human Immunology Biosciences a biotechnology company in the clinical stages of development has recently announced that the US Food and Drug Administration has granted Orphan Drug Designation

Mission Therapeutics Initiates Landmark Trial for MTX325, a Promising Therapy for Parkinson’s Disease

Friday, March 22, 2024

Mission Therapeutics a biotech company in the clinical stage has initiated the Phase I firstinhuman clinical trial of MTX its promising treatment aimed at modifying Parkinsons Disease

FDA Fast Tracks Phanes Therapeutics' PT886 for Metastatic Claudin 18.2-Positive Pancreatic Adenocarcinoma Treatment

Thursday, March 21, 2024

Phanes Therapeutics Inc a leading biotechnology company specializing in innovative oncology drug discovery and development made an announcement today regarding PT The US Food and Drug